Patients < 65 years | Patients ≥ 65 years | Patients < 70 years | Patients ≥ 70 years | Patients < 75 years | Patients ≥ 75 years | |
---|---|---|---|---|---|---|
Patients, n | 508 | 76 | 547 | 37 | 574 | 10 |
Through week 52 | ||||||
Mean duration of follow-up, weeks | 43.5 | 43.2 | 43.6 | 41.8 | 43.5 | 40.5 |
Mean number of golimumab infusions | 5.9 | 5.8 | 5.9 | 5.6 | 5.9 | 5.4 |
Patients with ≥ 1 AE | 355 (69.9) | 52 (68.4) | 379 (69.3) | 28 (75.7) | 397 (69.2) | 10 (100.0) |
Patients with infections | 214 (42.1) | 30 (39.5) | 227 (41.5) | 17 (45.9) | 239 (41.6) | 5 (50.0) |
Patients with ≥ 1 SAE | 45 (8.9) | 9 (11.8) | 49 (9.0) | 5 (13.5) | 50 (8.7) | 4 (40.0) |
Patients with serious infections | 7 (1.4) | 4 (5.3) | 10 (1.8) | 1 (2.7) | 10 (1.7) | 1 (10.0) |
Through week 112 | ||||||
Mean duration of follow-up, weeks | 96.6 | 90.9 | 96.4 | 88.7 | 96.2 | 76.9 |
Mean number of golimumab infusions | 12.0 | 11.3 | 12.0 | 10.9 | 12.0 | 9.4 |
Patients with ≥ 1 AE | 417 (82.1) | 61 (80.3) | 445 (81.4) | 33 (89.2) | 468 (81.5) | 10 (100.0) |
Patients with infections | 262 (51.6) | 42 (55.3) | 279 (51.0) | 25 (67.6) | 297 (51.7) | 7 (70.0) |
Patients with ≥ 1 SAE | 90 (17.7) | 19 (25.0) | 97 (17.7) | 12 (32.4) | 102 (17.8) | 7 (70.0) |
Patients with serious infections | 27 (5.3) | 9 (11.8) | 32 (5.9) | 4 (10.8) | 34 (5.9) | 2 (20.0) |